Datwyler is founding member of Alliance to Zero.
遗憾的是，此页面的内容没有中文版
用谷歌翻译June 11, 2021
Aim of net zero emissions across the pharmaceutical supply chain.
Eight companies representing the pharmaceutical supply chain for injectable devices announced the founding of the Alliance to Zero, a non-profit membership association for pharma supply chain companies that aims to facilitate the transition of the pharma sector to compliance with net zero emissions in line with the goal of the Paris Climate Agreement. Datwyler is a founding member of the Alliance to Zero.
The founders share the view that there is an urgent need to collaborate across the pharmaceutical supply chain and while there is much discussion in the pharma community today about sustainability and climate impact, substantial change among supply chain partners and manufacturers is not happening fast enough to reduce the emissions footprint. This is what the Alliance to Zero is committed to changing.
The following companies are among the founding members:
Datwyler, Harro Höfliger, HealthBeacon, Körber Pharma, Schott, Schreiner MediPharm, Sharp, Ypsomed.
With the already made and these planned investments, we are laying the foundation for future organic growth. We are very confident that we will achieve the communicated targets for 2021 of an increase in revenue to over CHF 1’100 million and an EBIT margin of around 15%.
CEO
In order to develop solutions that will have broad acceptance and a true positive impact on the pharmaceutical industry, the alliance recognises the need for deep and proactive collaboration across traditional company boundaries. The founding companies of the alliance represent key parts of the pharma supply chain, including component suppliers, machine suppliers and assembly/manufacturing service providers, as well as those involved in primary packaging to final device assembly and even collection after use.
The formation of this alliance is the first step in a challenging but urgent journey that our member organisations have committed themselves to. Enabling the launch of net zero pharmaceutical products in regulated markets will require companies like ours to transform our operations, products, services, logistics, innovations and investments. Our combined effort and our shared responsibility to ensure a real and lasting change is at the heart of the Alliance’s mission.
Sebastian Gerner, president of the Alliance to Zero
The alliance has begun development of a roadmap describing what a net zero emission concept for pharmaceutical manufacturing and supply chain would look like and the steps necessary to achieve it. This foundational work also includes agreement on harmonized language and principles for the assessment and control of the total emission footprint for the final pharmaceutical products, as well as the company-specific responsibilities.
The Alliance to Zero intends to involve, connect and coordinate suppliers, pharmaceutical companies, manufacturers and service providers along the supply chain and engage with academia and non-profit organisations with similar aims.
All information on the Alliance to Zero as well as its manifesto can be found on www.alliancetozero.com.
Enquiries
Guido Unternährer
VP Financial Communication & Investor Relations
Further information
Disclaimer financial information
The financial reports, presentations and media releases contain forward-looking statements. These statements reflect the Group’s current assessment of market conditions, economic developments and future events. However, these forward-looking statements are subject to economic, regulatory and political risks, uncertainties, assumptions and other factors over which Datwyler has no control. Unforeseen events could therefore cause actual developments and results to differ materially from those anticipated and from the information published in this documents. To that extent, all forward-looking statements contained in this documents are qualified in their entirety and Datwyler cannot guarantee that they will prove to be correct. Datwyler is under no obligation, and assumes no liability, to update any such forward-looking statements. This documents are neither an offer nor a solicitation to buy or sell Datwyler securities.